Simmons Bank Buys 1,602 Shares of Amgen Inc. $AMGN

Simmons Bank lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 7.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,108 shares of the medical research company’s stock after buying an additional 1,602 shares during the period. Simmons Bank’s holdings in Amgen were worth $7,891,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. E Fund Management Hong Kong Co. Ltd. boosted its stake in shares of Amgen by 300.2% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 1,757 shares of the medical research company’s stock valued at $606,000 after buying an additional 1,318 shares during the period. Western Wealth Management LLC boosted its stake in shares of Amgen by 3.2% in the fourth quarter. Western Wealth Management LLC now owns 4,297 shares of the medical research company’s stock valued at $1,407,000 after buying an additional 133 shares during the period. Allworth Financial LP boosted its stake in shares of Amgen by 6.1% in the fourth quarter. Allworth Financial LP now owns 41,798 shares of the medical research company’s stock valued at $13,681,000 after buying an additional 2,417 shares during the period. Castle Rock Wealth Management LLC boosted its stake in shares of Amgen by 0.9% in the fourth quarter. Castle Rock Wealth Management LLC now owns 8,983 shares of the medical research company’s stock valued at $3,065,000 after buying an additional 84 shares during the period. Finally, Rayburn West Financial Services LLC bought a new stake in shares of Amgen in the fourth quarter valued at approximately $2,906,000. 76.50% of the stock is currently owned by institutional investors.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on AMGN shares. Guggenheim cut their price target on Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a research note on Monday, May 4th. Argus boosted their price target on Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Barclays started coverage on Amgen in a research note on Friday, February 20th. They set an “equal weight” rating and a $350.00 target price for the company. Finally, Rothschild & Co Redburn upped their target price on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research note on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $356.35.

Amgen Stock Up 0.0%

NASDAQ AMGN opened at $336.45 on Thursday. The business has a fifty day moving average price of $351.05 and a two-hundred day moving average price of $342.80. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The stock has a market capitalization of $181.58 billion, a PE ratio of 23.41, a PEG ratio of 3.38 and a beta of 0.44.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same period in the prior year, the company earned $4.90 EPS. Amgen’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts expect that Amgen Inc. will post 22.36 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.15%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.